| o9dykainyu | Datum: Subota, 11-Jan-2014, 4:12 AM | Poruka # 1 |
|
Generalissimo
Grupa: Users
Poruka: 3207
Reputacija: 0
Status: Trenutno nije na sajtu
| Cellceutix to supply Poster on Novel Anti
BEVERLY, MA (Marketwired) 05/28/13
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company preoccupied with discovering small molecule drugs to remedy unmet medical conditions, including drugresistant cancers and autoimmune diseases, announces today that it's be presenting a poster to the company's p53activating drug, Kevetrin, with the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting being stored in Chicago, Illinois from May 31 through June 4, 2013.
An abstract of one's poster, titled, "A phase I, doseescalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a singular p53 targeted therapy, in patients with advanced solid tumors," is now <a href=http://fenntaler.nl/cd/newbalance.html>ニューバランス 996</a> available the ASCO website at DanaFarber Cancer Institute and Beth Israel Deaconess Facility," said Dr. are acutely aware which the oncology community and shareholders have a relatively strong interest regarding schedule, maximum tolerated dose and potential efficacy of Kevetrin, given its uniqueness and potential. The laboratory informed us that additional samples were necessary for analysis of Kevetrin's affect on biomarker p21, an earlystage indicator of efficacy. Those samples were given by a medical facility and with to always be delivered given that the trial progresses. Our company is hopeful that data shall be for here we are at ASCO. We anticipate the Proof Concept trial to get started on in August and take 60 days to always be completed. Because of the recent market enthusiasm towards Celgene's research of Apremilast, were needing to commence our clinical research of Prurisol."
As the innovative class of chemistry in medicine, <a href=http://fenntaler.nl/cd/aj.html>http://fenntaler.nl/cd/aj.html</a> Kevetrin" has significant chance to become a major breakthrough inside the dealing with solid tumors. Mechanism of action studies showed Kevetrin's unique opportunity to affect both wild and mutant styles of p53 (also known as the "Guardian Angel Gene" or use the "Guardian Angel of this Human Genome") and therefore Kevetrin strongly induced apoptosis (cell death), observed as activation of Caspase 3 and cleavage of PARP. Activation of p53 also induced apoptosis by allowing the expression of p53 target gene PUMA. p53 is an important tumor suppressor that <a href=http://fenntaler.nl/cd/agu.html>http://fenntaler.nl/cd/agu.html</a> acts to restrict proliferation by inducing cell cycle checkpoints, apoptosis, or cellular senescence.
In many more than 1 / 2 among all human carcinomas, p53 is fixed to use antitumor activities by mutations from the protein itself. Currently, you can get beyond Millions of of those with tumors that have inactivated p53, while the identical number have tumors from where the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers in the grand challenge of researching therapies which might restore the protein's protective function, which Kevetrin appears to be doing almost all the time.
More info for the medical trial, titled "A Phase 1, OpenLabel, DoseEscalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors," is out there at:
Headquartered in Beverly, Massachusetts, Cellceutix is actually a openly traded company using the symbol Regarded as emerging biopharmaceutical company devoted to the growth of its pipeline of compounds targeting areas of unmet medical need. Our flagship compound, Kevetrin can be an anticancer drug that's demonstrated the facility in preclinical studies to alter the p53 pathway and attack cancers who have proven proofed against today's cancer therapies (drugresistant cancers). Cellceutix also owns the rights to seven other drug compounds, including KM133, which is in development for psoriasis, and KM391 with the removing the the core signs of autism. Additional info can be found to the Cellceutix web page at
Into the extent that statements in this particular website will not be strictly historical, including statements in order to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the prosperity of the firm's development, events conditioned on stockholder and also other approval, or not satisfying you about future events, such statements are forwardlooking, so are made pursuant into the safe harbor provisions of your Private Securities Litigation Reform Act of 1995. The forwardlooking statements found in this release are governed by certain risks and uncertainties that can cause actual results to differ materially on the statements made. Securities and Exchange Commission.
[url=http://www.wmarketnyc.com/aj.html]エアジョーダン激安[/url]
|
| |
| |
